Cadario G, Ciprandi G, Di Cara G, Fadel R, Incorvaia C, Marcucci F, Marengo F, Puccinelli P, Sensi L, Strazzeri L, Frati F
Int J Immunopathol Pharmacol. 2008 Apr-Jun;21(2):471-3. doi: 10.1177/039463200802100229.
Sublingual immunotherapy (SLIT) is indicated in the treatment of allergic rhinitis and asthma. However, an issue scantly investigated is the patients satisfaction and the consequent compliance. This study is aimed at evaluating the possible differences of SLIT administered continuously or intermittently on several parameters: clinical efficacy, Quality of Life (QoL), satisfaction, compliance and safety. Forty allergic patients were treated for 12 months. The treatment was carried out by sublingual administration of an allergen extract of a 50% mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae at 10 and 300 IR/ml concentrations. Patients were randomly treated continuously or intermittently (i.e. 2 month treatment alternate to 2 month suspension). Both schedules were significantly effective in reducing allergic symptoms and improving QoL. Compliance and satisfaction were good in both groups. Local and systemic reactions were few, self-resolving, and mild in both schedules. Intergroup analysis did not reveal any difference between the two groups regarding these parameters. In conclusion, this preliminary study provides the evidence that also intermittent SLIT is as effective and safe as traditional continuous treatment. In addition, compliance and satisfaction are super-imposable in the two groups.
舌下免疫疗法（SLIT）适用于治疗过敏性鼻炎和哮喘。然而，一个鲜有研究的问题是患者的满意度以及随之而来的依从性。本研究旨在评估连续或间歇给予SLIT在几个参数方面可能存在的差异：临床疗效、生活质量（QoL）、满意度、依从性和安全性。40名过敏患者接受了12个月的治疗。治疗通过舌下给予浓度为10和300 IR/ml的粉尘螨和屋尘螨50%混合物的变应原提取物进行。患者被随机分为连续治疗组或间歇治疗组（即2个月治疗与2个月停药交替进行）。两种方案在减轻过敏症状和改善生活质量方面均显著有效。两组的依从性和满意度都很好。两种方案中局部和全身反应都很少，可自行缓解且程度较轻。组间分析未发现两组在这些参数上有任何差异。总之，这项初步研究提供了证据，表明间歇SLIT与传统连续治疗一样有效且安全。此外，两组的依从性和满意度相当。
